Advances in treating MLL-rearranged leukemia were also achieved by using small molecules to block the KMT2A binding site on Menin, a protein encoded by MEN1 and required for oncogenic transformation, leading to the inhibition of the aberrant leukemogenic transcription program [73,74,75,76,77]. The gene discussed is KMT2A; the disease is leukemia.